ACTRN12607000387426已完成3 期
The immunogenicity of 7-valent pneumococcal conjugate vaccine (PCV-7) in vulnerable elderly populations at high risk for invasive Pneumococcal disease.
Professor C Raina MacIntyre0 个研究点目标入组 315 人开始时间: 2007年7月24日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 315
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 60 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Hospitalized patients
排除标准
- •Younger than 60Previously vaccinated with pneumococcal vaccineAllergic reaction to one of the vaccine componentLife expectancy lees than 12 monthsSeen as unwell to be vaccinated
研究者
相似试验
招募中
不适用
The immunogenicity of 7-valent pneumococcal conjugate vaccine (PCV-7) in allogeneic bone marrow transplant recipientsPatient is scheduled to have allogeneic bone marrow transplantation (mathced realted or unrealted) excluding cord transplant.Surgery - BoneACTRN12605000773639Investigator driven study30
进行中（未招募）
不适用
Evaluation of immunogenicity of 7-valent Pneumococcal Conjugate Vaccine (Prevenar) and Hexavalent DtPa-HBV-IPV-Hib (InfaNrix Hexa), co-administered at the same time, versus Hexavalent vaccine, used in primary immunization schedule - NDHealthy childrenMedDRA version: 6.1Level: PTClassification code 10062163EUCTR2007-003692-39-ITAZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
进行中（未招募）
1 期
Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. - Immunogenicity of Prevenar in Ataxia telangiectasiaEUCTR2005-004122-70-GBGreat Ormond Street Hospital30
已完成
不适用
Inmunogenicity-PCV-Carriage-Venezuelan High Risk ChildreInfection Prophylaxis of Streptococcus pneumoniaeRPCEC00000150Servicio Autónomo Instituto de Biomedicina110
已完成
不适用
Pneumococcal Conjugate Vaccine (PCV) in HIV- Infected ChildrenHIVNCT01135082The HIV Netherlands Australia Thailand Research Collaboration90